Date published 
February 2012 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Hematological Cancer Therapies: Pipelines, Markets, and Business Considerations - Tables and Figures

 

Author: Lucy J. Sannes, PhD, MBA

TABLES
Table 2.1. Incidence and Mortality of Hematological Cancers in the United States, 2011 3
Table 3.1. Selected Chemotherapy Drugs that are FDA-Approved for Treatment of Cancer 19
Table 3.2. Selected Drugs Approved by the FDA for Treatment of Leukemia 23
Table 3.3. Selected Drugs Approved by the FDA for Treatment of Lymphoma, Including Hodgkin’s Disease and Non-Hodgkin’s Lymphoma (NHL) 37
Table 3.4. Selected Drugs Approved by the FDA for Treatment of Multiple Myeloma 46
Table 3.5. Selected Drugs Approved by the FDA for Treatment of Myelodysplastic Syndrome (MDS) 50
Table 3.6. Selected Drugs Approved by the FDA for Treatment of Myeloproliferative Diseases 53
Table 4.1. Selected Companies Developing Drugs for Leukemia 54
Table 5.1. Selected Companies Developing Drugs for Lymphomas 102
Table 6.1. Selected Companies Developing Drugs for Myeloma 145
Table 7.1. Selected Companies Developing Drugs for Myelodysplastic Syndromes 165
Table 8.1. Selected Companies Developing Drugs for Myeloproliferative Diseases 176
Table 9.1. Sales of Selected Drugs Used to Treat Hematological Cancers 186
Appendix: Selected Companies Developing Drugs for Hematological Cancers (General) 231